Radioembolización en hepatocarcinoma: a propósito de 53 casos

Heimbach, 2018, AASLD guidelines for the treatment of hepatocellular carcinoma, Hepatology., 67, 358, 10.1002/hep.29086 European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012;56:908-43. https://doi.org/10.1016/j.jhep.2011.12.001. Rich, 2017, Medical Management of Hepatocellular Carcinoma, J Oncol Pract., 13, 356, 10.1200/JOP.2017.022996 Forner, 2016, Diagnóstico y tratamiento del carcinoma hepatocelular. Actualización del documento de consenso de la AEEH, SEOM, SERAM, SERVEI y SETH, Med Clin (Barc)., 146, 511e1, 10.1016/j.medcli.2016.01.028 Wang, 2017, Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres, Int J Clin Pract., 71 Salem, 2018, Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience, Hepatology., 68, 1429, 10.1002/hep.29691 Sposito, 2018, The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future, Hepatobiliary Surg Nutr., 7, 487, 10.21037/hbsn.2018.10.06 Reguera-Berenguer, 2017, Downstaging de carcinoma hepatocelular bilobar tras radioembolización con microesferas de 90 Y como puente al trasplante hepático, Rev Esp Med Nucl Imagen Mol., 36, 329 Hamami, 2009, SPECT/CT with 99mTc-MAA in Radioembolization with 90Y Microspheres in Patients with Hepatocellular Cancer, J Nucl Med., 50, 688, 10.2967/jnumed.108.058347 Borggreve, 2016, Radioembolization: Is Prophylactic Embolization of Hepaticoenteric Arteries Necessary?. A Systematic Review, Cardiovasc Intervent Radiol., 39, 696, 10.1007/s00270-016-1310-9 Ho, 1996, Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours, Eur J Nucl Med., 23, 947, 10.1007/BF01084369 Kao, 2013, Post-radioembolization yttrium-90 PET/CT - part 1: diagnostic reporting, EJNMMI Res., 3, 1 Version 5.0. Common Terminology Criteria for Adverse Events (CTCAE). https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf (4/8/2020). Garin, 2013, Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept, Eur J Nucl Med Mol Imaging., 40, 1057, 10.1007/s00259-013-2395-x Gordon, 2018, Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma, Cardiovasc Intervent Radiol., 41, 1557, 10.1007/s00270-018-2008-y Meyer, 2017, Yttrium-90 radioembolization of unresectable hepatocellular carcinoma - a single center experience, Onco Targets Ther., 10, 4773, 10.2147/OTT.S137519 Hilgard, 2010, Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival, Hepatology., 52, 1741, 10.1002/hep.23944 Salem, 2010, Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes, Gastroenterology., 138, 52, 10.1053/j.gastro.2009.09.006 Iñarrairaegui, 2010, Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma, Int J Radiat Oncol Biol Phys., 77, 1441, 10.1016/j.ijrobp.2009.07.006 Bolondi, 2013, Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions, Semin Liver Dis., 32, 348, 10.1055/s-0032-1329906 Mazzaferro, 2013, Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study, Hepatology., 57, 1826, 10.1002/hep.26014 Sangro, 2011, Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation, Hepatology., 54, 868, 10.1002/hep.24451 Garin, 2012, Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results, J Nucl Med., 53, 255, 10.2967/jnumed.111.094235 Spreafico, 2018, Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion, J Hepatol., 68, 724, 10.1016/j.jhep.2017.12.026 Sangro, 2008, Liver disease induced by radioembolization of liver tumors, Cancer., 112, 1538, 10.1002/cncr.23339 Gil-Alzugaray, 2013, Prognostic factors and prevention of radioembolization-induced liver disease, Hepatology., 57, 1078, 10.1002/hep.26191 Rodríguez-Fraile, 2015, Radioembolización de tumores hepáticos con 90Y-microesferas, Rev Esp Med Nucl Imagen Mol., 34, 244 Salem, 2016, Y90 Radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma, Gastroenterology., 151, 1155, 10.1053/j.gastro.2016.08.029 Sangro, 2018, Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies, Eur J Nucl Med Mol Imaging., 45, 1721, 10.1007/s00259-018-3968-5